JTZ-951
Modify Date: 2024-01-09 11:54:52
JTZ-951 structure
|
Common Name | JTZ-951 | ||
|---|---|---|---|---|
| CAS Number | 1262132-81-9 | Molecular Weight | 340.333 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C17H16N4O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of JTZ-951Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM; Enarodustat has entered clinical trial for renal anemia. |
| Name | enarodustat |
|---|---|
| Synonym | More Synonyms |
| Description | Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM; Enarodustat has entered clinical trial for renal anemia. |
|---|---|
| Related Catalog | |
| Target |
EC50: 0.22 μM (factor prolyl hydroxylase)[1] |
| In Vitro | Enarodustat (JTZ-951) is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM. Enarodustat exhibits neither CYP (IC50 > 100 μM; CYP3A4/5, CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2B6) nor hERG (IC50 > 100 μM) inhibition[1]. |
| In Vivo | Enarodustat (1 and 3 mg/kg, p.o.) increases hemoglobin levels in a dose-dependent manner with daily oral dosing in rats[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H16N4O4 |
| Molecular Weight | 340.333 |
| Exact Mass | 340.117157 |
| LogP | 1.60 |
| Index of Refraction | 1.690 |
| JSK7TUA223 |
| enarodustat |
| Glycine, N-[[7-hydroxy-5-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl]- |
| N-{[7-Hydroxy-5-(2-phenylethyl)[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}glycine |